Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 27.07.2026 1 Abdom Radiol (NY) 1 Aktuelle Urol 1 Anal Bioanal Chem 4 Beijing Da Xue Xue Bao Yi Xue Ban 1 BMC Cancer 1 Cancer Immunol Immunother 1 Cell Signal 1 Clin Transl Oncol 1 Comb Chem High Throughput Screen 1 Cureus 1 Cutis 3 ESMO Open 1 Eur J Oncol Nurs 2 Eur Urol 1 Eur Urol Focus 2 Front Immunol 3 Front Oncol 1 Funct Integr Genomics 1 Genes Dis 1 Histol Histopathol 1 Int Braz J Urol 1 Int Cancer Conf J 2 Int J Biol Macromol 1 Int J Clin Oncol 1 Int J Urol 1 J Mol Diagn 1 J Transl Med 1 JAMA Netw Open 1 Mol Biol Rep 2 N Engl J Med 1 Nat Commun 2 Oncogene 1 Oncologist 1 Pharmacol Res 1 Sci Rep 1 Sci Transl Med 2 Transl Oncol 1 Tumori 3 Urol Oncol 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. YANG B, Yang R, Zhang W, Ren X, et al
   Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.
   Abdom Radiol (NY). 2026 Jul 20. doi: 10.1007/s00261-026-05679.
   PubMed         Abstract available
   
   

   
   Aktuelle Urol

2. SCHNABEL MJ, Grimm MO, Goebell PJ, Hellmis E, et al
   [Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer].
   Aktuelle Urol. 2026 Jul 24. doi: 10.1055/a-2883-3946.
   PubMed         Abstract available
   
   

   
   Anal Bioanal Chem

3. FROLOVA A, Vokuev M, Ikhalainen Y, Prosuntsova D, et al
   A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.
   Anal Bioanal Chem. 2026 Jul 24. doi: 10.1007/s00216-026-06678.
   PubMed         Abstract available
   
   

   
   Beijing Da Xue Xue Bao Yi Xue Ban

4. WANG Y, Song H, DU Y, Xu T, et al
   [CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:707-715.
   PubMed         Abstract available
   
   
5. DONG L, Peng Y, Song Y, Li X, et al
   [Development of a 36-gene signature for predicting recurrence in non-muscle-invasive bladder cancer and validation in a Chinese cohort].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:794-802.
   PubMed         Abstract available
   
   
6. JI J, Lai C, Wang F, Hu H, et al
   [Impact of coexistent low-grade components on the prognosis of high-grade non-muscle invasive bladder cancer].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:803-807.
   PubMed         Abstract available
   
   
7. ZHENG G, Peng Y, DU Y, Xu T, et al
   [Expression characteristics and clinical significance of ERBB2 in bladder urothelial carcinoma based on the TCGA database].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:818-826.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. KURAL S, Kumar L, Pathak AK, Singh S, et al
   Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
   BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
   PubMed         Abstract available
   
   

   
   Cancer Immunol Immunother

9. AMRANE K, Campedel L, Moinard-Butot F, Gout M, et al
   Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.
   Cancer Immunol Immunother. 2026;75:191.
   PubMed         Abstract available
   
   

   
   Cell Signal

10. HUI K, Wu S, Yue Y, Gu Y, et al
    Corrigendum to "RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer" [Cellular Signaling, 48 (2018) 38-44].
    Cell Signal. 2026 Jul 20:112730. doi: 10.1016/j.cellsig.2026.112730.
    PubMed        
    
    

    
    Clin Transl Oncol

11. PAN M, Tao T, Peng J, Zhang Y, et al
    Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis.
    Clin Transl Oncol. 2026 Jul 22. doi: 10.1007/s12094-026-04515.
    PubMed         Abstract available
    
    

    
    Comb Chem High Throughput Screen

12. SUN L, Yuan L
    Natural Biopeptide Hirudin Regulates Value-Added Metastasis of Bladder Cancer Cells by Activating PID1 Expression.
    Comb Chem High Throughput Screen. 2026.
    PubMed         Abstract available
    
    

    
    Cureus

13. NIKNAFS AM, Damron LF, Baclig NV, Iliopoulos M, et al
    Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates.
    Cureus. 2026;18:e111294.
    PubMed         Abstract available
    
    

    
    Cutis

14. MOECKEL C, Ferguson S
    Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance.
    Cutis. 2026;117:E14-E18.
    PubMed         Abstract available
    
    

    
    ESMO Open

15. POWLES T, Madjar K, Balas BI, Carter C, et al
    Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
    ESMO Open. 2026;11:107701.
    PubMed         Abstract available
    
    
16. ARAGON-CHING JB, Gupta S, Grivas P, Park SH, et al
    Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.
    ESMO Open. 2026;11:107776.
    PubMed         Abstract available
    
    
17. MAIORANO BA, Maruzzo M, Slusarczyk A, Subiela JD, et al
    Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.
    ESMO Open. 2026;11:108329.
    PubMed         Abstract available
    
    

    
    Eur J Oncol Nurs

18. ZHANG J, Li P, Liu L, Pan Z, et al
    Supportive-care burden among bladder cancer survivors in the United States: a nationally representative NHIS study.
    Eur J Oncol Nurs. 2026;84:103285.
    PubMed         Abstract available
    
    

    
    Eur Urol

19. DI BELLO F, Gallioli A, Breda A, Palou J, et al
    Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
    Eur Urol. 2026 Jul 23:S0302-2838(26)02275-X. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
20. LAZZERI M, Hurle R, Lughezzani G, Buffi NM, et al
    Re: Comprehensive Genome-wide Association Study Into Multiple Recurrence and Progression Risk in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Jul 22:S0302-2838(26)02266-9. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Focus

21. LEE DJ, Williams C, Soefje S, Flynn D, et al
    BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guerin Delivery for High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2026 Jul 22:S2405-4569(26)00116.
    PubMed         Abstract available
    
    

    
    Front Immunol

22. DONG Y, Su Y
    Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment.
    Front Immunol. 2026;17:1821743.
    PubMed         Abstract available
    
    
23. QIN J, Zhou H, Li X, Yin H, et al
    Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.
    Front Immunol. 2026;17:1786952.
    PubMed         Abstract available
    
    

    
    Front Oncol

24. GUO M, Zhou Y, Lin X, Xu Z, et al
    The prognostic impact of squamous differentiation in bladder cancer after radical cystectomy: a propensity score-matched comparative analysis of pure urothelial carcinoma, urothelial carcinoma with squamous differentiation, and squamous cell carcinoma
    Front Oncol. 2026;16:1890852.
    PubMed         Abstract available
    
    
25. ALHUBAISHY B, Beshawri I, Abulreish I, Alnajar O, et al
    Sequential gemcitabine-docetaxel in BCG-naive and BCG-failure non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1859461.
    PubMed         Abstract available
    
    
26. FERREIRA VG, Ehlert ME, Pacheco BS, Souza FSS, et al
    Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines.
    Front Oncol. 2026;16:1882402.
    PubMed         Abstract available
    
    

    
    Funct Integr Genomics

27. YANG J, Li X, Wang L, Wan S, et al
    Single-cell and spatial transcriptomics identify CAPG as a key driver of cisplatin resistance in bladder cancer.
    Funct Integr Genomics. 2026;26:197.
    PubMed         Abstract available
    
    

    
    Genes Dis

28. MENG XY, Shi MJ, Li S, Liu M, et al
    Tobacco's dual genomic footprints in bladder cancer revealed by multi-omics analysis: An SBS4-like LumU-enriched signature and smoking-driven HRD-related genomic instability.
    Genes Dis. 2025;13:102001.
    PubMed        
    
    

    
    Histol Histopathol

29. SAGLICAN Y, Unlu Y, Behzatoglu K
    Approach and nomenclature problems of extracutaneous basaloid neoplasias of visceral organs with three cases of basaloid carcinoma described for the first time in the urinary bladder.
    Histol Histopathol. 2026;41:1377-1385.
    PubMed         Abstract available
    
    

    
    Int Braz J Urol

30. FAVORITO LA
    Editorial Comment: Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Int Braz J Urol. 2026;52:e20269915.
    PubMed        
    
    

    
    Int Cancer Conf J

31. YASUDA K, Tsujino M, Yamasaki H, Kurahashi Y, et al
    Rapidly progressive synchronous multifocal gastrointestinal stenoses in bladder cancer: diagnostic challenges and clinical implications.
    Int Cancer Conf J. 2026;15:342-348.
    PubMed         Abstract available
    
    

    
    Int J Biol Macromol

32. QIN J, Li Z, Su L, Wen X, et al
    Retraction notice to "Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer" [Int. J. Biol. Macromol. 274 (2024) 133323].
    Int J Biol Macromol. 2026 Jul 22:153488. doi: 10.1016/j.ijbiomac.2026.153488.
    PubMed        
    
    
33. QIN J, Liao K, Huang L, Qiu R, et al
    Retraction notice to "Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization" [Int. J. Biol. Macromo
    Int J Biol Macromol. 2026 Jul 22:153573. doi: 10.1016/j.ijbiomac.2026.153573.
    PubMed        
    
    

    
    Int J Clin Oncol

34. EIGNER E, Fazaa N, Nsair A, Atallah M, et al
    Risk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysis.
    Int J Clin Oncol. 2026 Jul 18. doi: 10.1007/s10147-026-03140.
    PubMed         Abstract available
    
    

    
    Int J Urol

35. TAOKA R, Hayakawa N, Kimura T, Kikuchi E, et al
    Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.
    Int J Urol. 2026;33:e70570.
    PubMed         Abstract available
    
    

    
    J Mol Diagn

36. JIN D, Wang H, Jiang C, Zhang F, et al
    Non-Invasive Detection of Bladder Cancer via Urinary DNA Mutation and Methylation Profiling Using Modified qPCR.
    J Mol Diagn. 2026 Jul 21:S1525-1578(26)00122.
    PubMed         Abstract available
    
    

    
    J Transl Med

37. CHEN X, Sakatani T, Tanaka S, Contreras-Sanz A, et al
    A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.
    J Transl Med. 2026 Jul 21. doi: 10.1186/s12967-026-08681.
    PubMed         Abstract available
    
    

    
    JAMA Netw Open

38. HAMILTON-REEVES JM, Unger JM, Holzbeierlein JM, Lew DL, et al
    Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
    JAMA Netw Open. 2026;9:e2623622.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

39. SAJJADI S, Ramezani A, Alavimanesh S, Alipoor H, et al
    Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.
    Mol Biol Rep. 2026;53:1205.
    PubMed         Abstract available
    
    

    
    N Engl J Med

40. GALSKY MD, Valderrama BP, Maruzzo M, Font A, et al
    Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:338-348.
    PubMed         Abstract available
    
    
41. SRIDHAR SS
    A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
    N Engl J Med. 2026;395:402-404.
    PubMed        
    
    

    
    Nat Commun

42. ZHOU D, Li Y, Yan Z, Huang J, et al
    Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.
    Nat Commun. 2026;17:6902.
    PubMed         Abstract available
    
    

    
    Oncogene

43. SUN L, Yao Y, Gong S, Chen Z, et al
    YME1L1 degradation by TRIM21 inhibits bladder cancer proliferation, metastasis, and mitochondrial function.
    Oncogene. 2026 Jul 20. doi: 10.1038/s41388-026-03903.
    PubMed         Abstract available
    
    
44. CHENG Y, Chen Y, Wang J, Shu Z, et al
    DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer.
    Oncogene. 2026 Jul 24. doi: 10.1038/s41388-026-03915.
    PubMed         Abstract available
    
    

    
    Oncologist

45. NEOLA G, Flauto F, Caso C, Montuori G, et al
    The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
    Oncologist. 2026;31:oyag256.
    PubMed         Abstract available
    
    

    
    Pharmacol Res

46. SHI T, Wen C, Wang Z, Jiao Y, et al
    Celastrol's covalent strike on HK2: Breaking a metabolic-epigenetic circuit to impede bladder cancer.
    Pharmacol Res. 2026;231:108349.
    PubMed         Abstract available
    
    

    
    Sci Rep

47. TIAN H, Han X
    Sexual experience of urostomy patients with bladder cancer: a qualitative explorative study.
    Sci Rep. 2026 Jul 19. doi: 10.1038/s41598-026-62589.
    PubMed         Abstract available
    
    

    
    Sci Transl Med

48. ROUANNE M, Chen N, Mariuzza DL, Yang Z, et al
    Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.
    Sci Transl Med. 2026;18:eadv7600.
    PubMed         Abstract available
    
    

    
    Transl Oncol

49. DONG C, Fang Z, Han Y, Yin Y, et al
    Centrosome-related gene SPHK1 drives bladder cancer progression and therapeutic vulnerability.
    Transl Oncol. 2026;71:102926.
    PubMed         Abstract available
    
    
50. LI Y, Wu L, Shi J, Li W, et al
    Single-cell and spatial transcriptomics reveal SUV39H1 as a master epigenetic driver of immunosuppressive niche and stemness in bladder cancer.
    Transl Oncol. 2026;71:102929.
    PubMed         Abstract available
    
    

    
    Tumori

51. OUYANG B, Wu Z, Li J, Zhu G, et al
    Preliminary study on intravesical instillation of IL-12 mRNA lipid nanoparticles for the treatment of bladder cancer.
    Tumori. 2026 Jul 23:3008916261463130. doi: 10.1177/03008916261463130.
    PubMed         Abstract available
    
    

    
    Urol Oncol

52. FILIANOTI A, Costantini M, Rosca V, Mastroianni R, et al
    Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study.
    Urol Oncol. 2026 Jul 23:S1078-1439(26)00570.
    PubMed         Abstract available
    
    
53. NOWROOZI MR, Madani MH, Farzin A, Mazdak M, et al
    Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review.
    Urol Oncol. 2026 Jul 21:S1078-1439(26)00567.
    PubMed         Abstract available
    
    
54. OBEROI JK, Ballas LK, Tyson M, Singh P, et al
    Ideal candidates for bladder preservation in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 24:S1078-1439(26)00584.
    PubMed         Abstract available
    
    

    
    Urology

55. SMITH AK
    Editorial Comment on "Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer".
    Urology. 2026 Jul 22:S0090-4295(26)00458-9. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum